The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas

Neuro-Oncology

Volumn 9, Issue 1, 2007, Pages 47-52

  Gerber, David E ^a   Grossman, Stuart A ^a   Zeltzman, Michel ^a   Parisi, Michele A ^a   Kleinberg, Lawrence ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anaplastic astrocytoma; Anaplastic oligodendroglioma; Glioblastoma multiforme; Myelosuppression; Radiation therapy; Temozolomide; Thrombocytopenia

Indexed keywords

ANTICONVULSIVE AGENT; CARMUSTINE; CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DACARBAZINE; HEMOPOIETIC GROWTH FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MITOZOLOMIDE; PENTAMIDINE; PROTON PUMP INHIBITOR; TEMOZOLOMIDE; THYMOCYTE ANTIBODY; ALKYLATING AGENT; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CYTOPENIA; DRUG STRUCTURE; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ARTICLE; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 34047242618     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2006-024     Document Type: Review

References (21)

1. Ahmann, D.L., Bisel, H.F., Edmonson, J.H., Hahn, R.G., Eagan, R.T., O'Connell, M.J., and Frytak, S. (1976) Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma. Clin. Pharmacol. Ther. 19, 821-824.
2. Butowski, N., Prados, M.D., Lamborn, K.R., Larson, D.A., Sneed, P.K., Wara, W.M., Malec, M., Rabbitt, J., Page, M., and Chang, S.M. (2005) A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 61, 1454-1459.
3. Chang, S.M., Lamborn, K.R., Malec, M., Larson, D., Wara, W., Sneed, P., Rabbitt, J., Page, M., Nicholas, M.K., and Prados, M.D. (2004) Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 60, 353-357.
4. Cockcroft, D.W., and Gault, M.H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41.
5. Costanza, M.E., Nathanson, L., Schoenfeld, D., Wolter, J., Colsky, J., Regelson, W., Cunningham, T., and Sedransk, N. (1977) Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40, 1010-1015.
6. Devine, B.J. (1974) Gentamicin therapy. Drug. Intell. Clin. Pharm. 8, 650-655.
7. Doyle, T.J., Mikkelsen, T., Croteau, D., Ali, H., Anderson, J., Beasse, R., Rogers, L., Rosenblum, M., and Ryu, S. (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): Report of a phase II trial. J. Clin. Oncol. 23(suppl.), 1546 (abstract).
8. George, J.N., Raskob, G.E., Shah, S.R., Rizvi, M.A., Hamilton, S.A., Osborne, S., and Vondracek, T. (1998) Drug-induced thrombocytopenia: A systematic review of published case reports. Ann. Intern. Med. 129, 886-890.
9. Gutterman, J.U., Mavligit, G., Gottlieb, J.A., Burgess, M.A., McBride, C.E., Einhorn, L., Freireich, E.J., and Hersh, E.M. (1974) Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette-guerin. N. Engl. J. Med. 291, 592-597.
10. Kleeberg, U.R., and Schreml, W. (1976) Treatment of metastasising melanoma with a combination of cytostatic agents (in German) Dtsch. Med. Wochenschr. 101, 890-894.
11. Kleinberg, L., Grossman, S.A., Piantadosi, S., Zeltzman, M., and Wharam, M. (1999) The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 44, 535-543.
12. Mosteller, R.D. (1987) Simplified calculation of body-surface area. N. Engl. J. Med. 317, 1098.
13. Neijt, J.P., van der Burg, M.E., Guastalla, J.P., George, M., Piccart, M., Vermorken, J., Carnino, F., and Rotmensz, N. (1989) Phase II trial of mitozolomide in patients with advanced ovarian cancer: A study of the EORTC Gynecological Cancer Cooperative Group. Acta Oncol. 28, 663-665.
14. Newlands, E.S., Blackledge, G., Slack, J.A., Goddard, C., Brindley, C.J., Holden, L., and Stevens, M.F. (1985) Phase I clinical trial of mitozolomide. Cancer Treat. Rep. 69, 801-805.
15. Robinson, J.D., Lupkiewicz, S.M., Palenik, L., Lopez, L.M., and Ariet, M. (1983) Determination of ideal body weight for drug dosage calculations. Am. J. Hosp. Pharm. 40, 1016-1019.
16. Schering Corporation. (2005) Temodar® (temozolomide) capsules [product information]. Kenilworth, NJ: Schering Corporation.
17. Schornagel, J.H., Simonetti, G., Dubbelman, R., ten Bokkel Huinink, W.W., and McVie, J.G. (1990) Phase I study of mitozolomide on a once daily for 5 days schedule. Cancer Chemother. Pharmacol. 26, 237-238.
18. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E., and Mirimanoff, R.O., for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
19. Stupp, R., Mason, W.P., Van Den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M., Brandes, A.A., Cairncross, G., Lacombe, D., and Mirimanoff, R.O. (2004) Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. J Clin. Oncol. 22 (suppl.), 2 (abstract).
20. Su, Y.B., Sohn, S., Krown, S.E., Livingston, P.O., Wolchok, J.D., Quinn, C., Williams, L., Foster, T., Sepkowitz, K.A., and Chapman, P.B. (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J. Clin. Oncol. 22, 610-616.
21. Su, Y.W., Chang, M.C., Chiang, M.F., and Hsieh, R.K. (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol. 71, 315-318.